Simvastatin + acetylsalicylic acid (ASA) + omefas
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertriglyceridemia
Conditions
Hypertriglyceridemia
Trial Timeline
Nov 1, 2011 → Mar 1, 2012
NCT ID
NCT01486433About Simvastatin + acetylsalicylic acid (ASA) + omefas
Simvastatin + acetylsalicylic acid (ASA) + omefas is a phase 1 stage product being developed by AstraZeneca for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01486433. Target conditions include Hypertriglyceridemia.
What happened to similar drugs?
1 of 20 similar drugs in Hypertriglyceridemia were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01486433 | Phase 1 | Completed |
Competing Products
20 competing products in Hypertriglyceridemia